(Amendment No. 1)*
If the filing person has previously filed a statement on Schedule
13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e),
240.13d-1(f) or 240.13d-1(g), check the following box. ☐
The information required on the remainder of this cover page shall
not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
1
|
Names of Reporting Persons.
OrbiMed Advisors LLC
|
2
|
Check the Appropriate Box if a Member of a Group (See Instructions).
(a) o
(b) o
|
|
3
|
SEC Use Only
|
4
|
Source of Funds (See Instructions)
AF
|
5
|
Check if Disclosure of Legal Proceedings Is Required Pursuant to
Items 2(d) or 2(e)
|
o
|
6
|
Citizenship or Place of Organization
Delaware
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
Sole Voting Power
0
|
8
|
Shared Voting Power
4,163,347
|
9
|
Sole Dispositive Power
0
|
10
|
Shared Dispositive Power
4,163,347
|
11
|
Aggregate Amount Beneficially Owned by Each Reporting Person
4,163,347
|
12
|
Check if the Aggregate Amount in Row (11) Excludes Certain Shares
(See Instructions)
|
o
|
13
|
Percent of Class Represented by Amount in Row (11)
19.8%*
|
14
|
Type of Reporting Person (See Instructions)
IA
|
|
|
|
|
|
* This percentage is calculated based upon 21,043,984 shares of common
stock outstanding of Graybug Vision, Inc. (the “Issuer”), as set forth in the Issuer’s Form 10-K filed
with the Securities and Exchange Commission on March 5, 2021.
1
|
Names of Reporting Persons.
OrbiMed Capital GP VI LLC
|
2
|
Check the Appropriate Box if a Member of a Group (See Instructions).
(a) o
(b) o
|
|
3
|
SEC Use Only
|
4
|
Source of Funds (See Instructions)
AF
|
5
|
Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
|
o
|
6
|
Citizenship or Place of Organization
Delaware
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
Sole Voting Power
0
|
8
|
Shared Voting Power
4,163,347
|
9
|
Sole Dispositive Power
0
|
10
|
Shared Dispositive Power
4,163,347
|
11
|
Aggregate Amount Beneficially Owned by Each Reporting Person
4,163,347
|
12
|
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
|
o
|
13
|
Percent of Class Represented by Amount in Row (11)
19.8%*
|
14
|
Type of Reporting Person (See Instructions)
OO
|
|
|
|
|
|
* This percentage is calculated based upon 21,043,984 shares of common
stock outstanding of Graybug Vision, Inc. (the “Issuer”), as set forth in the Issuer’s Form 10-K filed
with the Securities and Exchange Commission on March 5, 2021.
CUSIP No. 38942Q103
|
|
|
|
|
|
|
|
|
1
|
Names of Reporting Persons.
OrbiMed Capital LLC
|
|
2
|
Check the Appropriate Box if a Member of a Group (See Instructions).
(a) o
(b) o
|
|
|
3
|
SEC Use Only
|
|
4
|
Source of Funds (See Instructions)
AF
|
|
5
|
Check if Disclosure of Legal Proceedings Is Required Pursuant to
Items 2(d) or 2(e)
|
o
|
|
6
|
Citizenship or Place of Organization
Cayman Islands
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
Sole Voting Power
73,500
|
|
8
|
Shared Voting Power
0
|
|
9
|
Sole Dispositive Power
73,500
|
|
10
|
Shared Dispositive Power
0
|
|
11
|
Aggregate Amount Beneficially Owned by Each Reporting Person
73,500
|
|
12
|
Check if the Aggregate Amount in Row (11) Excludes Certain Shares
(See Instructions)
|
o
|
|
13
|
Percent of Class Represented by Amount in Row (11)
0.4%*
|
|
14
|
Type of Reporting Person (See Instructions)
IA
|
|
|
|
|
|
|
|
|
|
* This percentage is calculated based upon 21,043,984 shares of common
stock outstanding of Graybug Vision, Inc. (the “Issuer”), as set forth in the Issuer’s Form 10-K filed
with the Securities and Exchange Commission on March 5, 2021.
Item 1. Security and Issuer
This Amendment No. 1 (“Amendment
No. 1”) supplements and amends the statement on Schedule 13D (the “Statement”) originally filed with
the Securities and Exchange Commission (the “SEC”) on October 5, 2020. This Statement relates to the common
stock, value $.0001 per share (the “Shares”) of Graybug Vision,
Inc., a corporation organized under the laws of Delaware (the “Issuer”
), with its principal executive offices located at 275 Shoreline Drive, Suite 450, Redwood City, CA 94065 The Shares are
listed on the NASDAQ Global Market under the ticker symbol “GRAY”. Information given in response to each item shall
be deemed incorporated by reference in all other items, as applicable.
Based
on the Issuer’s annual report on Form 10-K filed with the SEC on March 5, 2021, there were 21,043,984 outstanding
Shares as of February 26, 2021. This number is greater than the total number of outstanding Shares reported on the Issuer’s Rule
424(b)(4) Prospectus, filed with the SEC on September 25, 2020. As a result of the increase in the Issuer’s
total number of outstanding Shares and the transactions described in Item 5(c) below, the beneficial ownership of the outstanding
Shares of the Issuer held by the Reporting Persons was reduced by more than 1% since the last filing.
Item 2. Identity and Background
(a) This Schedule 13D is
being filed by OrbiMed Advisors LLC (“OrbiMed Advisors”), OrbiMed Capital GP VI LLC (“OrbiMed GP”),
and OrbiMed Capital LLC (“OrbiMed Capital”) (collectively, the “Reporting Persons”).
(b) — (c),
(f) OrbiMed Advisors, a limited liability company organized under the laws of Delaware and a registered investment adviser under
the Investment Advisers Act of 1940, as amended, is the managing member or general partner of certain entities as more particularly
described in Item 6 below. OrbiMed Advisors has its principal offices at 601 Lexington Avenue, 54th Floor, New York, New
York 10022.
OrbiMed GP, a limited liability company organized
under the laws of Delaware, is the general partner of a limited partnership as more particularly described in Item 6 below.
OrbiMed GP has its principal offices at 601 Lexington Avenue, 54th Floor, New York, New York 10022.
OrbiMed Capital, a limited
liability company organized under the laws of Delaware and a registered investment adviser under the Investment Advisers Act of
1940, as amended, is the investment adviser of certain entities as more particularly described in Item 6 below. OrbiMed Capital
has its principal offices at 601 Lexington Avenue, 54th Floor, New York, New York 10022.
The directors and executive
officers of OrbiMed Advisors, OrbiMed Capital, and OrbiMed GP are set forth on Schedules I, II, and III, respectively, attached
hereto. Schedules I, II and III set forth the following information with respect to each such person:
(i) name;
(ii) business
address;
(iii) present
principal occupation of employment and the name, principal business and address of any corporation or other organization in which
such employment is conducted; and
(iv) citizenship.
(d) — (e) During
the last five years, neither the Reporting Persons nor any Person named in Schedules I through III has been (i) convicted in a
criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial
or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or
final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws
or finding any violation with respect to such laws.
Item 3. Source and Amount of Funds or Other Consideration
Not applicable.
Item 4. Purpose of Transaction
This statement relates
to the acquisition of Shares by the Reporting Persons. The Shares acquired by the Reporting Persons were acquired for the purpose
of making an investment in the Issuer and not with the intention of acquiring control of the Issuer’s business on behalf
of the Reporting Persons’ respective advisory clients.
The Reporting Persons from
time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer’s business,
financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general
and those for the Issuer’s Shares in particular, as well as other developments and other investment opportunities.
Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate
in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the
Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of
the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors,
the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise
acquired by the Reporting Persons either in the open market or in privately negotiated transactions.
Except as set forth in this Amendment No. 1,
the Reporting Persons have not formulated any plans or proposals which relate to or would result in: (a) the acquisition
by any person of additional securities of the Issuer or the disposition of securities of the Issuer, (b) an extraordinary corporate
transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries, (c) a sale or transfer
of a material amount of the assets of the Issuer or any of its subsidiaries, (d) any change in the present Board of Directors or
management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies
on the board, (e) any material change in the Issuer’s capitalization or dividend policy of the Issuer, (f) any other material
change in the Issuer’s business or corporate structure, (g) any change in the Issuer’s charter or bylaws or other instrument
corresponding thereto or other action which may impede the acquisition of control of the Issuer by any person, (h) causing a class
of the Issuer’s securities to be deregistered or delisted from a national securities exchange or to cease to be authorized
to be quoted in an inter-dealer quotation system of a registered national securities association, (i) a class of equity securities
of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act or (j) any action similar
to any of those enumerated above.
Item 5. Interest in Securities of the Issuer
(a) — (b) As
of the date of this filing, OrbiMed Private Investments VI, LP (“OPI VI”), a limited partnership organized under the
laws of Delaware, holds 4,163,347 Shares, constituting approximately 19.8% of the issued and outstanding Shares. OrbiMed
GP is the general partner of OPI VI, pursuant to the terms of the limited partnership agreement of OPI VI, and OrbiMed Advisors
is the managing member of OrbiMed GP, pursuant to the terms of the limited liability company agreement of OrbiMed GP. As
a result, OrbiMed Advisors and OrbiMed GP share power to direct the vote and disposition of the Shares held by OPI VI and may be
deemed directly or indirectly, including by reason of their mutual affiliation, to be the beneficial owners of the Shares held
by OPI VI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L.
Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI VI.
In addition, OrbiMed Advisors
and OrbiMed GP, pursuant to their authority under the limited partnership agreement of OPI VI, caused OPI VI to enter into the
agreements referred to in Item 6 below.
As of the date of this filing, BIOG, a publicly-listed
investment trust organized under the laws of England, holds 73,500 Shares constituting approximately 0.4% of the issued and outstanding
Shares. OrbiMed Capital is the investment advisor of BIOG. As a result, OrbiMed Capital has the power to direct the vote
and disposition of the Shares held by BIOG and may be deemed directly or indirectly, including by reason of mutual affiliation,
to be the beneficial owner of the Shares held by BIOG. OrbiMed Capital disclaims any beneficial ownership over the shares
of the other Reporting Persons. OrbiMed Capital exercises this investment and voting power through a management committee
comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares
held by BIOG.
(c)
Seller
|
Date of Transaction
|
Transaction
|
Number of Shares
|
Price Per Share
|
BIOG
|
February 19, 2021
|
Sold
|
1,300
|
$25.34
|
BIOG
|
February 22, 2021
|
Sold
|
1,900
|
$22.91
|
BIOG
|
March 1, 2021
|
Sold
|
2,896
|
$19.48
|
BIOG
|
March 1, 2021
|
Sold
|
100
|
$19.55
|
BIOG
|
March 1, 2021
|
Sold
|
10,200
|
$19.38
|
BIOG
|
March 2, 2021
|
Sold
|
7,800
|
$19.02
|
BIOG
|
March 3, 2021
|
Sold
|
10,699
|
$18.21
|
BIOG
|
March 5, 2021
|
Sold
|
16,900
|
$16.10
|
BIOG
|
March 8, 2021
|
Sold
|
12,371
|
$15.91
|
BIOG
|
March 9, 2021
|
Sold
|
144,834
|
$8.01
|
BIOG
|
March 25, 2021
|
Sold
|
30,000
|
$6.17
|
Except as disclosed above,
the Reporting Persons have not effected any transactions during the past sixty (60) days in any Shares.
(d) Not applicable.
(e) Not applicable.
Item 6. Contracts, Arrangements, Understandings or Relationships
with Respect to Securities of the Issuer
In addition to the relationships
between the Reporting Persons described in Items 2 and 5 above, OrbiMed GP is the general partner of OPI VI, pursuant to the terms
of the limited partnership agreement of OPI VI. Pursuant to this agreement and relationship, OrbiMed GP has discretionary
investment management authority with respect to the assets of OPI VI. Such authority includes the power to vote and otherwise dispose
of securities held by OPI VI. The number of outstanding Shares of the Issuer attributable to OPI VI is 4,163,347 Shares.
OrbiMed GP, pursuant to its authority under the limited partnership agreement of OPI VI, may be considered to hold indirectly 4,163,347
Shares.
OrbiMed Advisors is the
managing member of OrbiMed GP, pursuant to the terms of the limited liability company agreement of OrbiMed GP. Pursuant to these
agreements and relationships, OrbiMed Advisors and OrbiMed GP have discretionary investment management authority with respect to
the assets of OPI VI. Such authority includes the power of OrbiMed GP to vote and otherwise dispose of securities held by
OPI VI. The number of outstanding Shares attributable to OPI VI is 4,163,347 Shares. OrbiMed Advisors, pursuant to
its authority under the terms of the limited liability company agreement of OrbiMed GP, may also be considered to hold indirectly
4,163,347 Shares.
OrbiMed Capital is the
investment advisor to BIOG. OrbiMed Capital may be deemed to have voting and investment power over the securities held by BIOG.
Such authority includes the power of OrbiMed Capital to vote and otherwise dispose of securities held by BIOG. The number
of outstanding Shares attributable to BIOG is 73,500 Shares. OrbiMed Capital, as the investment advisor to BIOG, may also be considered
to hold indirectly 73,500 Shares.
Investors’ Rights Agreement
In addition, OPI
VI and certain other stockholders of the Issuer entered into an Amended and Restated Investors’ Rights Agreement with the
Issuer (the “Investors’ Rights Agreement”), dated as of July 31, 2019. Pursuant to the Investors’
Rights Agreement and subject to the terms and conditions therein, the parties agreed that:
Demand Registration Rights
At any time beginning
six months following the date of the effective date of the registration statement of the IPO, the holders of at least 25% of the
registrable securities then outstanding of the Issuer (or a lesser percent if the anticipated aggregate offering price, net of
selling expenses, would exceed $20 million) may make a written request that the Issuer register some or all of their registrable
securities, subject to certain specified conditions and exceptions. The Issuer is required to use commercially reasonable efforts
to effect the registration and will pay all registration expenses, other than underwriting discounts and commissions, related to
any demand registration. The Issuer is not obligated to effect more than two of these registrations.
Piggyback Registration Rights
Whenever
the Issuer proposes to file a registration statement under the Securities Act, including a registration statement on Form S-3 as
discussed below, other than with respect to certain excluded registrations, OPI VI will be entitled to notice of the registration
and have the right, subject to limitations that the underwriters may impose on the number of Shares included in the registration,
to include the Shares held by OPI VI in the registration.
Form S-3 Registration Rights
At any time after
the Issuer is qualified to file a registration statement on Form S-3 under the Securities Act, and subject to limitations and conditions
specified in the Investors’ Rights Agreement, holders of at least 15% of the registrable securities then outstanding may
make a written request that the Issuer prepare and file a registration statement on Form S-3 covering their Shares, so long as
the aggregate price to the public equal or exceeds $5 million. The Issuer is not obligated to effect more than two of these Form
S-3 registrations in any 12-month period.
The foregoing description of the Investors’
Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Investors’
Rights Agreement, which is filed as Exhibit 2 and incorporated herein by reference.
Item 7. Material to Be Filed as Exhibits
Exhibit
|
Description
|
1.
|
Joint Filing Agreement among OrbiMed Advisors LLC, OrbiMed Capital LLC, and OrbiMed Capital GP VI LLC.
|
2.
|
Amended and Restated Investors’ Rights Agreement by and among the Issuer and each of the persons listed on Schedule A thereto, dated as of July 31, 2019 (incorporated by reference to Exhibit 4.2 to the Issuer’s Registration Statement on Form S-1 (SEC 333-248611), filed with the SEC on September 4, 2020).
|
Signature
After reasonable inquiry and to the best of
my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: March 26, 2021
|
ORBIMED ADVISORS LLC
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Carl L. Gordon
|
|
|
|
Name: Carl L. Gordon
|
|
|
|
Title: Member
|
|
|
|
|
|
|
ORBIMED CAPITAL GP VI LLC
|
|
|
|
|
|
|
By:
|
ORBIMED ADVISORS LLC, its managing member
|
|
|
|
|
|
By:
|
/s/ Carl L. Gordon
|
|
|
|
Name: Carl L. Gordon
|
|
|
|
Title: Member of OrbiMed Advisors LLC
|
|
|
ORBIMED CAPITAL LLC
|
|
|
|
|
|
|
By:
|
/s/ Carl L. Gordon
|
|
|
|
Name: Carl L. Gordon
|
|
|
|
Title: Member
|
|
SCHEDULE I
The
names and present principal occupations of each of the executive officers and directors of OrbiMed Advisors LLC are set forth below.
Unless otherwise noted, each of these persons is a United States citizen and has a business address of 601 Lexington Avenue, 54th
Floor, New York, NY 10022.
Name
|
Position with Reporting Person
|
Principal Occupation
|
|
|
|
|
|
|
Carl L. Gordon
|
Member
|
Member
OrbiMed Advisors LLC
|
|
|
|
Sven H. Borho
German and Swedish Citizen
|
Member
|
Member
OrbiMed Advisors LLC
|
|
|
|
Jonathan T. Silverstein
|
Member
|
Member
OrbiMed Advisors LLC
|
|
|
|
W. Carter Neild
|
Member
|
Member
OrbiMed Advisors LLC
|
|
|
|
Geoffrey C. Hsu
|
Member
|
Member
OrbiMed Advisors LLC
|
|
|
|
C. Scotland Stevens
|
Member
|
Member
OrbiMed Advisors LLC
|
|
|
|
David P. Bonita
|
Member
|
Member
OrbiMed Advisors LLC
|
|
|
|
Trey Block
|
Chief Financial Officer
|
Chief Financial Officer
OrbiMed Advisors LLC
|
SCHEDULE II
The
names and present principal occupations of each of the executive officers and directors of OrbiMed Capital LLC are set forth below.
Unless otherwise noted, each of these persons is a United States citizen and has a business address of 601 Lexington Avenue, 54th
Floor, New York, NY 10022.
Name
|
Position with Reporting Person
|
Principal Occupation
|
|
|
|
|
|
|
Carl L. Gordon
|
Member
|
Member
OrbiMed Capital LLC
|
|
|
|
Sven H. Borho
German and Swedish Citizen
|
Member
|
Member
OrbiMed Capital LLC
|
|
|
|
Jonathan T. Silverstein
|
Member
|
Member
OrbiMed Capital LLC
|
|
|
|
W. Carter Neild
|
Member
|
Member
OrbiMed Capital LLC
|
|
|
|
Geoffrey C. Hsu
|
Member
|
Member
OrbiMed Capital LLC
|
|
|
|
C. Scotland Stevens
|
Member
|
Member
OrbiMed Capital LLC
|
|
|
|
David P. Bonita
|
Member
|
Member
OrbiMed Capital LLC
|
|
|
|
Trey Block
|
Chief Financial Officer
|
Chief Financial Officer
OrbiMed Capital LLC
|
SCHEDULE III
The business
and operations of OrbiMed Capital GP VI LLC are managed by the executive officers and directors of its managing member, OrbiMed
Advisors LLC, set forth in Schedule I attached hereto.
EXHIBIT INDEX
Exhibit
|
Description
|
1.
|
Joint Filing Agreement among OrbiMed Advisors LLC, OrbiMed Capital LLC, and OrbiMed Capital GP VI LLC.
|
2.
|
Amended and Restated Investors’ Rights Agreement by and among the Issuer and each of the persons listed on Schedule A thereto, dated as of July 31, 2019 (incorporated by reference to Exhibit 4.2 to the Issuer’s Registration Statement on Form S-1 (SEC 333-248611), filed with the SEC on September 4, 2020).
|